FOXP3 and inflammatory bowel disease: This is the first time that this effect of a corticosteroid is demonstrated in the CD4+/CD25− cell population and this phenomenon may be relevant in the control of bronchial inflammation since CD4+/CD25− T lymphocytes ectopically expressing Foxp3 acquire the function to control inflammation in experimentally induced inflammatory bowel disease and to down-regulate the proliferation of CD4+/CD25− T lymphocytes in vitro [36].